Intercept Pharma (ICPT) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Intercept (ICPT) Shares Likely to Keep Moving Higher, Says RBC
May 11, 2015 3:53 PM EDTRBC Capital reiterated an Outperform rating on Intercept Pharmaceuticals (NASDAQ: ICPT) with a price target of $490. Comments follow the company's Q1 results and comments from management. Analyst Michael J. Yee thinks catalysts will keep shares moving higher.
"We reiterate our Outperform and see catalysts ahead that are likely to keep stock moving higher: (1) we continue to... More
Intercept (ICPT) FV Target Lifted to $363 at Janney Capital; 'Enjoying this Ride'
May 11, 2015 1:30 PM EDTJanney Capital analyst Chiara Russo bumped her fair value target on Buy-rated Intercept Pharmaceuticals (NASDAQ: ICPT) to $363.00 (from $350.00) following in-line Q1 results.
Russo commented, "1Q15 could have gone differently for ICPT. Instead, everything went very right. OCA for NASH officially received... More
Intercept's (ICPT) Rolling NDA, MAA Submissions for OCA Appear on Track; Needham & Company Affirms at 'Buy'
May 11, 2015 12:47 PM EDTNeedham & Company affirms Intercept Pharma (NASDAQ: ICPT) with a Buy rating and $500 price target following Q1 results issued Monday morning.
Ahead of the opening bell, Intercept reported Q1 EPS of ($1.78) and revenue of $405,000, versus the analyst EPS estimate of ($1.69) and revenue of $1.7... More
